Thiol redox homeostasis in neurodegenerative disease

Redox Biology

Volumn 5, Issue , 2015, Pages 186-194

  McBean, Gethin J ^a   Aslan, Mutay ^b   Griffiths, Helen R ^c   Torrão, Rita C ^c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b AKDENIZ UNIVERSITY   (Turkey)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

Cysteine; Glutaredoxin; Glutathione; Neurodegenerative disease; Peroxiredoxin; Thioredoxin

Indexed keywords

CYSTEINE; GLUTAMIC ACID; GLUTATHIONE; MEMBRANE PROTEIN; PROTEIN PRX2; PROTEIN PRX6; PROTEIN TRX1; THIOL; THIOREDOXIN; UNCLASSIFIED DRUG; GLUTAREDOXIN; PEROXIREDOXIN; THIOL DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL SURVIVAL; DEGENERATIVE DISEASE; EXTRACELLULAR SPACE; GLAUCOMA; HOMEOSTASIS; HUMAN; NERVE CELL; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; CHEMISTRY; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

CYSTEINE; GLAUCOMA; GLUTAREDOXINS; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATION-REDUCTION; PEROXIREDOXINS; SULFHYDRYL COMPOUNDS; THIOREDOXINS;

EID: 84930936945     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.04.004     Document Type: Review

References (110)

1. Gu F., Chauhan V., Chauhan A. Glutathione redox imbalance in brain disorders. Current Opinion in Clinical Nutrition and Metabolic Care 2015, 18:89-95.
2. Ruszkiewicz J., Albrecht P. Changes in mitochondrial antioxidant systems in neurodegenerative disease and acute brain disorders. Neurochemistry International 2015.
3. Aoyama K., Nakaki T. Impaired glutathione synthesis in neurodegeneration. International Journal of Molecular Science 2013, 14(10):21021-21044. http://www.ncbi.nlm.nih.gov/pubmed/24145751, 10.3390/ijms141021021.
4. Reddie K.G., Carroll K.S. Expanding the functional diversity of proteins through cysteine oxidation. Current Opinion in Chemical Biology 2008, 12(6):746-754. http://www.ncbi.nlm.nih.gov/pubmed/18804173, 10.1016/j.cbpa.2008.07.028.
5. Reddie K.G., Seo Y.H., Muse Iii W.B., Leonard S.E., Carroll K.S. A chemical approach for detecting sulfenic acid-modified proteins in living cells. Molecular Biosystems 2008, 4(6):521-531. http://www.ncbi.nlm.nih.gov/pubmed/18493649, 10.1039/b719986d.
6. Ratnayake S., Dias I.H., Lattman E., Griffiths H.R. Stabilising cysteinyl thiol oxidation and nitrosation for proteomic analysis. Journal of Proteomics 2013, 92:160-170. http://www.ncbi.nlm.nih.gov/pubmed/23796488, 10.1016/j.jprot.2013.06.019.
7. Fernandez-Fernandez S., Almeida A., Bolaños J.P. Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochemical Journal 2012, 443(1):3-11. http://www.ncbi.nlm.nih.gov/pubmed/22417747, 10.1042/BJ20111943.
8. Herrero-Mendez A., Almeida A., Fernández E., Maestre C., Moncada S., Bolaños J.P. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nature Cell Biology 2009, 11(6):747-752. http://www.ncbi.nlm.nih.gov/pubmed/19448625, 10.1038/ncb1881.
9. Mieyal J.J., Gallogly M.M., Qanungo S., Sabens E.A., Shelton M.D. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxidants and Redox Signaling 2008, 10(11):1941-1988. http://www.ncbi.nlm.nih.gov/pubmed/18774901, 10.1089/ars.2008.2089.
10. Roede J.R., Uppal K., Liang Y., Promislow D.E., Wachtman L.M., Jones D.P. Characterization of plasma thiol redox potential in a common marmoset model of aging. Redox Biology 2013, 18:387-393.
11. Zhu J.W., Yuan J.F., Yang H.M., Wang S.T., Zhang C.G., Sun L.L., Yang H., Zhang H. Extracellular cysteine (cys)/cystine (CySS) redox regulates metabotropic glutamate receptor 5 activity. Biochimie 2012, 94(3):617-627. http://www.ncbi.nlm.nih.gov/pubmed/21964032, 10.1016/j.biochi.2011.09.013.
12. Ghosh D., Brewer G.J. External cys/cySS redox state modification controls the intracellular redox state and neurodegeneration via Akt in aging and Alzheimer's disease mouse model neurons. Journal of Alzheimer's Disease 2014, 42(1):313-324. http://www.ncbi.nlm.nih.gov/pubmed/24844688, 10.3233/JAD-132756.
13. Diwakar L., Ravindranath V. Inhibition of cystathionine-gamma-lyase leads to loss of glutathione and aggravation of mitochondrial dysfunction mediated by excitatory amino acid in the CNS. Neurochemistry International 2007, 50(2):418-426. http://www.ncbi.nlm.nih.gov/pubmed/17095121, 10.1016/j.neuint.2006.09.014.
14. Kandil S., Brennan L., McBean G.J. Glutathione depletion causes a JNK and p38MAPK-mediated increase in expression of cystathionine-gamma-lyase and upregulation of the transsulfuration pathway in C6 glioma cells. Neurochemistry International 2010, 56(4):611-619. http://www.ncbi.nlm.nih.gov/pubmed/20060865, 10.1016/j.neuint.2010.01.004.
15. Sagara J.I., Miura K., Bannai S. Maintenance of neuronal glutathione by glial cells. Journal of Neurochemistry 1993, 61(5):1672-1676. http://www.ncbi.nlm.nih.gov/pubmed/8228986, 10.1111/j.1471-4159.1993.tb09802.x.
16. Dringen R., Pfeiffer B., Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. Journal of Neuroscience 1999, 19(2):562-569. http://www.ncbi.nlm.nih.gov/pubmed/9880576.
17. Banjac A., Perisic T., Sato H., Seiler A., Bannai S., Weiss N., Kölle P., Tschoep K., Issels R.D., Daniel P.T., Conrad M., Bornkamm G.W. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene 2008, 27(11):1618-1628. http://www.ncbi.nlm.nih.gov/pubmed/17828297, 10.1038/sj.onc.1210796.
18. Lewerenz J., Baxter P., Kassubek R., Albrecht P., Van Liefferinge J., Westhoff M.A., Halatsch M.E., Karpel-Massler G., Meakin P.J., Hayes J.D., Aronica E., Smolders I., Ludolph A.C., Methner A., Conrad M., Massie A., Hardingham G.E., Maher P. Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - a pathway active in glioblastomas and epilepsy. Antioxidants and Redox Signaling 2014, 20:2907-2922.
19. Conrad M., Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids 2012, 42(1):231-246. http://www.ncbi.nlm.nih.gov/pubmed/21409388, 10.1007/s00726-011-0867-5.
20. De Blundel D., Schallier A., Loyens E., Fernando R., Miyashita H., Van Liefferinge J., Vermoessen K., Bannai S., Sato H., Michotte Y., Smolders I., Massie A. Loss of system xc- formula does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. Journal of Neuroscience 2011, 31:3592-5803.
21. Bridges R., Lutgen V., Lobner D., Baker D.A. Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacological Reviews 2012, 64(3):780-802. http://www.ncbi.nlm.nih.gov/pubmed/22759795, 10.1124/pr.110.003889.
22. Moran M.M., McFarland K., Melendez R.I., Kalivas P.W., Seamans J.K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. Journal of Neuroscience 2005, 25(27):6389-6393. http://www.ncbi.nlm.nih.gov/pubmed/16000629, 10.1523/JNEUROSCI.1007-05.2005.
23. De Groot J.F., Sontheimer H. Glutamate and the biology of gliomas. Glia 2011, 59(8):1181-1189. http://www.ncbi.nlm.nih.gov/pubmed/21192095, 10.1002/glia.21113.
24. Bridges C.C., Hu H., Miyauchi S., Siddaramappa U.N., Ganapathy M.E., Ignatowicz L., Maddox D.M., Smith S.B., Ganapathy V. Induction of cystine-glutamate transporter xc- by human immunodeficiency virus type 1 transactivator protein Tat in retinal pigment epithelium. Investigative Ophthalmology and Visual Science 2004, 45(9):2906-2914. http://www.ncbi.nlm.nih.gov/pubmed/15326101, 10.1167/iovs.03-1355.
25. Pampliega O., Domercq M., Soria F.N., Villoslada P., Rodríguez-Antigüedad A., Matute C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. Journal of Neuroinflammation 2011, 8:63. http://www.ncbi.nlm.nih.gov/pubmed/21639880, 10.1186/1742-2094-8-63.
26. Gnana-Prakasam J.P., Tawfik A., Romej M., Ananth S., Martin P.M., Smith S.B., Ganapathy V. Iron-mediated retinal degeneration in haemojuvelin-knockout mice. Biochemical Journal 2012, 441(2):599-608. http://www.ncbi.nlm.nih.gov/pubmed/21943374, 10.1042/BJ20111148.
27. Gnana-Prakasam J.P., Thangaraju M., Liu K., Ha Y., Martin P.M., Smith S.B., Ganapathy V. Absence of iron-regulatory protein Hfe results in hyperproliferation of retinal pigment epithelium: role of cystine/glutamate exchanger. Biochemical Journal 2009, 424(2):243-252. http://www.ncbi.nlm.nih.gov/pubmed/19715555, 10.1042/BJ20090424.
28. Marcus H.J., Carpenter K.L., Price S.J., Hutchinson P.J. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. Journal of Neuro-Oncology 2010, 97(1):11-23. http://www.ncbi.nlm.nih.gov/pubmed/19714445, 10.1007/s11060-009-9990-5.
29. Savaskan N.E., Heckel A., Hahnen E., Engelhorn T., Doerfler A., Ganslandt O., Nimsky C., Buchfelder M., Eyüpoglu I.Y. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nature Medicine 2008, 14(6):629-632. http://www.ncbi.nlm.nih.gov/pubmed/18469825, 10.1038/nm1772.
30. Chung W.J., Lyons S.A., Nelson G.M., Hamza H., Gladson C.L., Gillespie G.Y., Sontheimer H. Inhibition of cystine uptake disrupts the growth of primary brain tumors. Journal of Neuroscience 2005, 25(31):7101-7110. http://www.ncbi.nlm.nih.gov/pubmed/16079392, 10.1523/JNEUROSCI.5258-04.2005.
31. Gout P.W., Kang A.R., Buckley C.R., Bruchovsky N., Buckley A.R. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001, 15(10):1633-1640. http://www.ncbi.nlm.nih.gov/pubmed/11587223, 10.1038/sj.leu.2402238.
32. Sleire L., Skeie B.S., Netland I.A., Førde H.E., Dodoo E., Selheim F., Leiss L., Heggdal J.I., Pedersen P.H., Wang J., Enger P.Ø Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system xc-, leading to glutathione depletion. Oncogene 2015, epub ahead of print]. 10.1038/onc.2015.60.
33. Qin S., Colin C., Hinners I., Gervais A., Cheret C., Mallat M. System xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. Journal of Neuroscience 2006, 26(12):3345-3356. http://www.ncbi.nlm.nih.gov/pubmed/16554485, 10.1523/JNEUROSCI.5186-05.2006.
34. Mesci P., Zaïdi S., Lobsiger C.S., Millecamps S., Escartin C., Seilhean D., Sato H., Mallat M., Boillée S. System xc- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain 2015, 138(1):53-68. http://www.ncbi.nlm.nih.gov/pubmed/25384799, 10.1093/brain/awu312.
35. Crish S.D., Calkins D.J. Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. Neuroscience 2011, 176:1-11. http://www.ncbi.nlm.nih.gov/pubmed/21187126, 10.1016/j.neuroscience.2010.12.036.
36. Quigley H.A. Glaucoma. Lancet 2011, 377(9774):1367-1377. http://www.ncbi.nlm.nih.gov/pubmed/21453963, 10.1016/S0140-6736(10)61423-7.
37. He Z., Vingrys A.J., Armitage J.A., Nguyen C.T., Bui B.V. Chronic hypertension increases susceptibility to acute IOP challenge in rats. Investigative Ophthalmology and Visual Science 2014, 55(12):7888-7895. http://www.ncbi.nlm.nih.gov/pubmed/25370512, 10.1167/iovs.14-15207.
38. Saccá S.C., Izzotti A., Rossi P., Traverso C. Glaucomatous outflow pathway and oxidative stress. Experimental Eye Research 2007, 84(3):389-399. http://www.ncbi.nlm.nih.gov/pubmed/17196589, 10.1016/j.exer.2006.10.008.
39. Aslan M., Dogan S., Kucuksayan E. Oxidative stress and potential applications of free radical scavengers in glaucoma. Redox Report 2013, 18(2):76-87. http://www.ncbi.nlm.nih.gov/pubmed/23485101, 10.1179/1351000212Y.0000000033.
40. Sucher N.J., Lipton S.A., Dreyer E.B. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Research 1997, 37(24):3483-3493. http://www.ncbi.nlm.nih.gov/pubmed/9425525, 10.1016/S0042-6989(97)00047-3.
41. Gupta N., Yücel Y.H. Glaucoma as a neurodegenerative disease. Current Opinion in Ophthalmology 2007, 18(2):110-114. http://www.ncbi.nlm.nih.gov/pubmed/17301611, 10.1097/ICU.0b013e3280895aea.
42. Wax M.B., Tezel G. Immunoregulation of retinal ganglion cell fate in glaucoma. Experimental Eye Research 2009, 88(4):825-830. http://www.ncbi.nlm.nih.gov/pubmed/19233171, 10.1016/j.exer.2009.02.005.
43. Athanasiou D., Aguilá M., Bevilacqua D., Novoselov S.S., Parfitt D.A., Cheetham M.E. The cell stress machinery and retinal degeneration. FEBS Letters 2013, 587(13):2008-2017. http://www.ncbi.nlm.nih.gov/pubmed/23684651, 10.1016/j.febslet.2013.05.020.
44. Shin E.S., Sorenson C.M., Sheibani N. Diabetes and retinal vascular dysfunction. Journal of Ophthalmic and Vision Research 2014, 9(3):362-373. http://www.ncbi.nlm.nih.gov/pubmed/25667739, 10.4103/2008-322X.143378.
45. Ganea E., Harding J.J. Glutathione-related enzymes and the eye. Current Eye Research 2006, 31(1):1-11. http://www.ncbi.nlm.nih.gov/pubmed/16421014, 10.1080/02713680500477347.
46. Aslan M., Cort A., Yucel I. Oxidative and nitrative stress markers in glaucoma. Free Radical Biology and Medicine 2008, 45(4):367-376. http://www.ncbi.nlm.nih.gov/pubmed/18489911, 10.1016/j.freeradbiomed.2008.04.026.
47. L.M.Bova,M.H.Sweeney,Jamie J.F.Truscott,R.J. Major changes in human ocular UV protection with age. Investigative Ophthalmology and Vision Science 2001, 42(1):200-205. Jamie. http://www.ncbi.nlm.nih.gov/pubmed/11133868.
48. Moreno M.C., Campanelli J., Sande P., Sánez D.A., Keller Sarmiento M.I., Rosenstein R.E. Retinal oxidative stress induced by high intraocular pressure. Free Radical Biology and Medicine 2004, 37(6):803-812. http://www.ncbi.nlm.nih.gov/pubmed/15384194, 10.1016/j.freeradbiomed.2004.06.001.
49. Gherghel D., Griffiths H.R., Hilton E.J., Cunliffe I.A., Hosking S.L. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Investigative Ophthalmology and Vision Science 2005, 46(3):877-883. http://www.ncbi.nlm.nih.gov/pubmed/15728543, 10.1167/iovs.04-0777.
50. Gherghel D., Mroczkowska S., Qin L. Reduction in blood glutathione levels occurs similarly in patients with primary-open angle or normal tension glaucoma. Investigative Ophthalmology and Vision Science 2013, 54(5):3333-3339. http://www.ncbi.nlm.nih.gov/pubmed/23599328, 10.1167/iovs.12-11256.
51. Mazzetti A.P., Fiorile M.C., Primavera A., Lo Bello M. Glutathione transferases and neurodegenerative diseases. Neurochemistry International 2015, 82:10-18. 10.1016/j.neuint.2015.01.008.
52. Bagnis A., Izzotti A., Centofanti M., Saccá S.C. Aqueous humor oxidative stress proteomic levels in primary open angle glaucoma. Experimental Eye Research 2012, 103:55-62. http://www.ncbi.nlm.nih.gov/pubmed/22974818, 10.1016/j.exer.2012.07.011.
53. Yang J., Tezel G., Patil R.V., Romano C., Wax M.B. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Investigative Ophthalmology and Vision Science 2001, 42(6):1273-1276. http://www.ncbi.nlm.nih.gov/pubmed/11328739.
54. Almasieh M., Wilson A.M., Morquette B., Cueva Vargas J.L., Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Progress in Retinal and Eye Research 2012, 31(2):152-181. http://www.ncbi.nlm.nih.gov/pubmed/22155051, 10.1016/j.preteyeres.2011.11.002.
55. Dreyer E.B., Zurakowski D., Schumer R.A., Podos S.M., Lipton S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Archives of Ophthalmology 1996, 114(3):299-305. http://www.ncbi.nlm.nih.gov/pubmed/8600890, 10.1001/archopht.1996.01100130295012.
56. Dun Y., Mysona B., Van Ells T., Amarnath L., Ola M.S., Ganapathy V., Smith S.B. Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress. Cell Tissue Research 2006, 324(2):189-202. http://www.ncbi.nlm.nih.gov/pubmed/16609915, 10.1007/s00441-005-0116-x.
57. Allen E.M., Mieyal J.J. Protein-thiol oxidation and cell death: regulatory role of glutaredoxins. Antioxidants and Redox Signaling 2012, 17(12):1748-1763. http://www.ncbi.nlm.nih.gov/pubmed/22530666, 10.1089/ars.2012.4644.
58. Garcia-Garcia A., Zavala-Flores L., Rodriguez-Rocha H., Franco R. Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease. Antioxidants and Redox Signaling 2012, 17(12):1764-1784. http://www.ncbi.nlm.nih.gov/pubmed/22369136, 10.1089/ars.2011.4501.
59. Sabens Liedhegner E.A., Gao X.H., Mieyal J.J. Mechanisms of altered redox regulation in neurodegenerative diseases - focus on S-glutathionylation. Antioxidants and Redox Signaling 2012, 16(6):543-566. http://www.ncbi.nlm.nih.gov/pubmed/22066468, 10.1089/ars.2011.4119.
60. Nomura K., Lee M., Banks C., Lee G., Morris B.J. An ASK1-p38 signalling pathway mediates hydrogen peroxide-induced toxicity in NG108-15 neuronal cells. Neuroscience Letters 2013, 549:163-167. http://www.ncbi.nlm.nih.gov/pubmed/23742763, 10.1016/j.neulet.2013.05.045.
61. Drechsel D.A., Patel M. Respiration-dependent H2O2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. Journal of Biological Chemistry 2010, 285(36):27850-27858. http://www.ncbi.nlm.nih.gov/pubmed/20558743, 10.1074/jbc.M110.101196.
62. Lopert P., Day B.J., Patel M. Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS One 2012, 7(11):e50683. http://www.ncbi.nlm.nih.gov/pubmed/23226354, 10.1371/journal.pone.0050683.
63. Lopert P., Patel M. Nicotinamide nucleotide transhydrogenase (Nnt) links the substrate requirement in brain mitochondria for hydrogen peroxide removal to the thioredoxin/peroxiredoxin (Trx/Prx) system. Journal of Biological Chemistry 2014, 289(22):15611-15620. http://www.ncbi.nlm.nih.gov/pubmed/24722990, 10.1074/jbc.M113.533653.
64. Kenchappa R.S., Ravindranath V. Glutaredoxin is essential for maintenance of brain mitochondrial complex I: Studies with MPTP. FASEB Journal 2003, 17(6):717-719. http://www.ncbi.nlm.nih.gov/pubmed/12594173, 10.1096/fj.02-0771fje.
65. Diwakar L., Kenchappa R.S., Annepu J., Ravindranath V. Downregulation of glutaredoxin but not glutathione loss leads to mitochondrial dysfunction in female mice CNS: implications in excitotoxicity. Neurochemistry International 2007, 51(1):37-46. http://www.ncbi.nlm.nih.gov/pubmed/17512091, 10.1016/j.neuint.2007.03.008.
66. Lee D.W., Kaur D., Chinta S.J., Rajagopalan S., Andersen J.K. A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. Antioxidants and Redox Signaling 2009, 11(9):2083-2094. http://www.ncbi.nlm.nih.gov/pubmed/19290777, 10.1089/ARS.2009.2489.
67. Karunakaran S., Saeed U., Ramakrishnan S., Koumar R.C., Ravindranath V. Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Research 2007, 1185:8-17. http://www.ncbi.nlm.nih.gov/pubmed/17961515, 10.1016/j.brainres.2007.09.019.
68. Saeed U., Durgadoss L., Valli R.K., Joshi D.C., Joshi P.G., Ravindranath V. Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: implication in neurodegenerative diseases. PLoS One 2008, 3(6):e2459. http://www.ncbi.nlm.nih.gov/pubmed/18560520, 10.1371/journal.pone.0002459.
69. Ferri A., Fiorenzo P., Nencini M., Cozzolino M., Pesaresi M.G., Valle C., Sepe S., Moreno S., Carrì M.T. Glutaredoxin 2 prevents aggregation of mutant SOD1 in mitochondria and abolishes its toxicity. Human Molecular Genetics 2010, 19(22):4529-4542. http://www.ncbi.nlm.nih.gov/pubmed/20829229, 10.1093/hmg/ddq383.
70. Bouldin S.D., Darch M.A., Hart P.J., Outten C.E. Redox properties of the disulfide bond of human Cu,Zn superoxide dismutase and the effects of human glutaredoxin 1. Biochemical Journal 2012, 446(1):59-67. http://www.ncbi.nlm.nih.gov/pubmed/22651090, 10.1042/BJ20120075.
71. Brasil A.A., Belati A., Mannarino S.C., Panek A.D., Eleutherio E.C., Pereira M.D. The involvement of GSH in the activation of human Sod1 linked to FALS in chronologically aged yeast cells. FEMS Yeast Research 2013, 13(5):433-440. http://www.ncbi.nlm.nih.gov/pubmed/23496883, 10.1111/1567-1364.12045.
72. Saeed U., Ray A., Valli R.K., Kumar A.M., Ravindranath V. DJ-1 loss by glutaredoxin but not glutathione depletion triggers Daxx translocation and cell death. Antioxidants and Redox Signaling 2010, 13(2):127-144. http://www.ncbi.nlm.nih.gov/pubmed/20014998, 10.1089/ars.2009.2832.
73. Lopert P., Patel M. Brain mitochondria from DJ-1 knockout mice show increased respiration-dependent hydrogen peroxide consumption. Redox Biology 2014, 2:667-672. http://www.ncbi.nlm.nih.gov/pubmed/24936441, 10.1016/j.redox.2014.04.010.
74. Akterin S., Cowburn R.F., Miranda-Vizuete A., Jiménez A., Bogdanovic N., Winblad B., Cedazo-Minguez A. Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death and Differentiation 2006, 13(9):1454-1465. http://www.ncbi.nlm.nih.gov/pubmed/16311508, 10.1038/sj.cdd.4401818.
75. Sabens E.A., Distler A.M., Mieyal J.J. Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease. Biochemistry 2010, 49(12):2715-2724. http://www.ncbi.nlm.nih.gov/pubmed/20141169, 10.1021/bi9018658.
76. Masutani H., Bai J., Kim Y.C., Yodoi J. Thioredoxin as a neurotrophic cofactor and an important regulator of neuroprotection. Molecular Neurobiology 2004, 29(3):229-242. http://www.ncbi.nlm.nih.gov/pubmed/15181236, 10.1385/MN:29:3:229.
77. Ungerstedt J., Du Y., Zhang H., Nair D., Holmgren A. In vivo redox state of human thioredoxin and redox shift by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Free Radical Biology and Medicine 2012, 53(11):2002-2007. http://www.ncbi.nlm.nih.gov/pubmed/23010496, 10.1016/j.freeradbiomed.2012.09.019.
78. Holmgren A., Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochemical and Biophysical Research Communications 2010, 396(1):120-124. http://www.ncbi.nlm.nih.gov/pubmed/20494123, 10.1016/j.bbrc.2010.03.083.
79. Hashemy S.I., Holmgren A. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. Journal of Biological Chemistry 2008, 283(32):21890-21898. http://www.ncbi.nlm.nih.gov/pubmed/18544525, 10.1074/jbc.M801047200.
80. Holmgren A. Thioredoxin. Annual Review of Biochemistry 1985, 54:237-271. http://www.ncbi.nlm.nih.gov/pubmed/3896121, 10.1146/annurev.bi.54.070185.001321.
81. Lillig C.H., Holmgren A. Thioredoxin and related molecules - from biology to health and disease. Antioxidants and Redox Signaling 2007, 9(1):25-47. http://www.ncbi.nlm.nih.gov/pubmed/17115886, 10.1089/ars.2007.9.25.
82. Powis G., Montfort W.R. Properties and biological activities of thioredoxins. Annual Review of Biophysics and Biomolecular Structure 2001, 30:421-455. http://www.ncbi.nlm.nih.gov/pubmed/11441809, 10.1146/annurev.biophys.30.1.421.
83. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(8):3633-3638. http://www.ncbi.nlm.nih.gov/pubmed/9108029, 10.1073/pnas.94.8.3633.
84. Kabe Y., Ando K., Hirao S., Yoshida M., Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxidants and Redox Signaling 2005, 7(3-4):395-403. http://www.ncbi.nlm.nih.gov/pubmed/15706086, 10.1089/ars.2005.7.395.
85. Zschauer T.C., Kunze K., Jakob S., Haendeler J., Altschmied J. Oxidative stress-induced degradation of thioredoxin-1 and apoptosis is inhibited by thioredoxin-1-actin interaction in endothelial cells. Arteriosclerosis, Thrombosis and Vascular Biology 2011, 31(3):650-656. http://www.ncbi.nlm.nih.gov/pubmed/21212402, 10.1161/ATVBAHA.110.218982.
86. Im J.Y., Lee K.W., Junn E., Mouradian M.M. DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex. Neuroscience Research 2010, 67:203-208. http://www.ncbi.nlm.nih.gov/pubmed/20385180, 10.1016/j.neures.2010.04.002.
87. Waak J., Weber S.S., Görner K., Schall C., Ichijo H., Stehle T., Kahle P.J. Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase 1. Journal of Biological Chemistry 2009, 284(21):14245-14257. http://www.ncbi.nlm.nih.gov/pubmed/19293155, 10.1074/jbc.M806902200.
88. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T.M., Thomas B., Ko H.S., Sasaki M., Ischiropoulos H., Przedborski S., Dawson T.M., Dawson V.L. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(37):14807-14812. http://www.ncbi.nlm.nih.gov/pubmed/17766438, 10.1073/pnas.0703219104.
89. Niso-Santano M., González-Polo R.A., Bravo-San Pedro J.M., Gómez-Sánchez R., Lastres-Becker I., Ortiz-Ortiz M.A., Soler G., Morán J.M., Cuadrado A., Fuentes J.M. Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis. Free Radical Biology and Medicine 2010, 48(10):1370-1381. http://www.ncbi.nlm.nih.gov/pubmed/20202476, 10.1016/j.freeradbiomed.2010.02.024.
90. +, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. Toxicological Sciences 2007, 95(1):163-171. http://www.ncbi.nlm.nih.gov/pubmed/17018646, 10.1093/toxsci/kfl125.
91. Yang W., Tiffany-Castiglioni E., Koh H.C., Son I.H. Paraquat activates the IRE1/ASK1/JNK cascade associated with apoptosis in human neuroblastoma SH-SY5Y cells. Toxicology Letters 2009, 191(2-3):203-210. http://www.ncbi.nlm.nih.gov/pubmed/19735704, 10.1016/j.toxlet.2009.08.024.
92. Liu Z., Jing Y., Yin J., Mu J., Yao T., Gao L. Downregulation of thioredoxin reductase 1 expression in the substantia nigra pars compacta of Parkinson's disease mice. Neural Regeneration Research 2013, 8(35):3275-3283. http://www.ncbi.nlm.nih.gov/pubmed/25206649, 10.3969/j.issn.1673-5374.2013.35.002.
93. Zeng X.S., Jia J.J., Kwon Y., Wang S.D., Bai J. The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease. Free Radical Biology and Medicine 2014, 67:10-18. http://www.ncbi.nlm.nih.gov/pubmed/24140863, 10.1016/j.freeradbiomed.2013.10.013.
94. Umeda-Kameyama Y., Tsuda M., Ohkura C., Matsuo T., Namba Y., Ohuchi Y., Aigaki T. Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in drosophila. Journal of Biological Chemistry 2007, 282(15):11180-11187. http://www.ncbi.nlm.nih.gov/pubmed/17301052, 10.1074/jbc.M700937200.
95. Meng L., Wong J.H., Feldman L.J., Lemaux P.G., Buchanan B.B. A membrane-associated thioredoxin required for plant growth moves from cell to cell, suggestive of a role in intercellular communication. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(8):3900-3905. http://www.ncbi.nlm.nih.gov/pubmed/20133584, 10.1073/pnas.0913759107.
96. Carilho Torrao R.B., Dias I.H., Bennett S.J., Dunston C.R., Griffiths H.R. Healthy ageing and depletion of intracellular glutathione influences T cell membrane thioredoxin-1 levels and cytokine secretion. Chemistry Central Journal 2013, 7(1):150. http://www.ncbi.nlm.nih.gov/pubmed/24007191, 10.1186/1752-153X-7-150.
97. Arodin L., Lamparter H., Karlsson H., Nennesmo I., Björnstedt M., Schröder J., Fernandes A.P. Alteration of thioredoxin and glutaredoxin in the progression of Alzheimer's disease. Journal of Alzheimer's Disease 2014, 39(4):787-797. http://www.ncbi.nlm.nih.gov/pubmed/24270206, 10.3233/JAD-131814.
98. Munemasa Y., Ahn J.H., Kwong J.M., Caprioli J., Piri N. Redox proteins thioredoxin 1 and thioredoxin 2 support retinal ganglion cell death in glaucoma. Gene Therapy 2009, 16:17-25.
99. Hattori F., Oikawa S. Peroxiredoxins in the central nervous system. Subcellular Biochemistry 2007, 44:357-374. http://www.ncbi.nlm.nih.gov/pubmed/18084903, 10.1007/978-1-4020-6051-9_17.
100. Yao J., Taylor M., Davey F., Ren Y., Aiton J., Coote P., Fang F., Chen J.X., Yan S.D., Gunn-Moore F.J. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Molecular and Cellular Neuroscience 2007, 35(2):377-382. http://www.ncbi.nlm.nih.gov/pubmed/17490890, 10.1016/j.mcn.2007.03.013.
101. Randall L.M., Manta B., Hugo M., Gil M., Batthyàny C., Trujillo M., Poole L.B., Denicola A. Nitration transforms a sensitive peroxiredoxin 2 into a more active and robust peroxidase. Journal of Biological Chemistry 2014, 289(22):15536-15543. http://www.ncbi.nlm.nih.gov/pubmed/24719319, 10.1074/jbc.M113.539213.
102. Fang J., Nakamura T., Cho D.H., Gu Z., Lipton S.A. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(47):18742-18747. http://www.ncbi.nlm.nih.gov/pubmed/18003920, 10.1073/pnas.0705904104.
103. Kim I.K., Lee K.J., Rhee S., Seo S.B., Pak J.H. Protective effects of peroxiredoxin 6 overexpression on amyloid beta-induced apoptosis in PC12 cells. Free Radical Research 2013, 47(10):836-846. http://www.ncbi.nlm.nih.gov/pubmed/23937564, 10.3109/10715762.2013.833330.
104. Yun H.M., Jin P., Han J.Y., Lee M.S., Han S.B., Oh K.W., Hong S.H., Jung E.Y., Hong J.T. Acceleration of the development of Alzheimer's disease in amyloid beta-infused peroxiredoxin 6 overexpression transgenic mice. Molecular Neurobiology 2013, 48(3):941-951. http://www.ncbi.nlm.nih.gov/pubmed/23771816, 10.1007/s12035-013-8479-6.
105. Lee Y.M., Park S.H., Shin D.I., Hwang J.Y., Park B., Park Y.J., Lee T.H., Chae H.Z., Jin B.K., Oh T.H., Oh Y.J. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. Journal of Biological Chemistry 2008, 283(15):9986-9998. http://www.ncbi.nlm.nih.gov/pubmed/18250162, 10.1074/jbc.M800426200.
106. Hu X., Weng Z., Chu C.T., Zhang L., Cao G., Gao Y., Signore A., Zhu J., Hastings T., Greenamyre J.T., Chen J. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. Journal of Neuroscience 2011, 31(1):247-261. http://www.ncbi.nlm.nih.gov/pubmed/21209210, 10.1523/JNEUROSCI.4589-10.2011.
107. Angeles D.C., Gan B.H., Onstead L., Zhao Y., Lim K.L., Dachsel J., Melrose H., Farrer M., Wszolek Z.K., Dickson D.W., Tan E.K. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Human Mutation 2011, 32(12):1390-1397. http://www.ncbi.nlm.nih.gov/pubmed/21850687, 10.1002/humu.21582.
108. Johnson W.M., Yao C., Siedlak S.L., Wang W., Zhu X., Caldwell G.A., Wilson-Delfosse A.L., Mieyal J.J., Chen S.G. Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease. Human Molecular Genetics 2015, 24(5):1322-1335. http://www.ncbi.nlm.nih.gov/pubmed/25355420, 10.1093/hmg/ddu542.
109. Power J.H., Asad S., Chataway T.K., Chegini F., Manavis J., Temlett J.A., Jensen P.H., Blumbergs P.C., Gai W.P. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathology 2008, 115(6):611-622. http://www.ncbi.nlm.nih.gov/pubmed/18386021, 10.1007/s00401-008-0373-3.
110. Yoshida Y., Yoshikawa A., Kinumi T., Ogawa Y., Saito Y., OHara K., Yamamoto H., Imai Y., Niki E. Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomarkers. Neurobiology of Aging 2009, 30(2):174-185. http://www.ncbi.nlm.nih.gov/pubmed/17688973, 10.1016/j.neurobiolaging.2007.06.012.